Cardiology

 

The Endocrinology Network® Cardiology clinical resource center is a hub of news related to cardiovascular health that is relevant to clinicians interested in endocrinology. A leading cause of death among diabetics and a threat for many with other endocrine diseases, this page will host relevant content about cardiology and cardiovascular disease including guideline updates, new studies and breakthroughs, and clinical perspective for practicing clinicians.

Pedometers, Activity Trackers Linked to Greater Improvements in Physical Activity in Randomized Trials

July 26, 2021

A systematic review and meta-analysis of randomized trials suggest use of physical activity trackers, such as pedometers and accelerometers, were linked to increased levels of physical activity versus non-use in patients with cardiometabolic conditions.

Prepregnancy Cardiovascular Risk Factors Play Role in Risk of Adverse Maternal, Fetal Outcomes

July 22, 2021

Analysis of more than 18 million pregnancies sheds light on the impact various prepregnancy cardiovascular risk factors, including BMI, smoking status, and diabetes, can have on risk of adverse maternal and fetal outcomes.

Dapagliflozin Safe and Effective in Stage 4 Chronic Kidney Disease, DAPA-CKD Analysis Finds

July 20, 2021

A prespecified analysis of patients with stage 4 CKD from DAPA-CKD suggests the magnitude of effects seen with dapagliflozin use among these patients was similar to that seen among patients with normal to moderately impaired kidney function from the trial.

FDA Panel Votes Against Roxadustat, Cites Risk of Thrombotic Events

July 16, 2021

The subject of a July 15 meeting, the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 13-1 and 12-2 against recommending approval of roxadustat for treatment of anemia in adult patients with chronic kidney disease not on dialysis and on dialysis, respectively.

Whole Grain Intake Linked to More Preferable Cardiometabolic Profile in Aging Adults, USDA-Funded Study Finds

July 13, 2021

An analysis of data from the Framingham Heart Study Offspring Cohort by investigators at the USDA Human Nutrition Research Center on Aging suggests greater consumption of whole grains was associated with a more preferable cardiometabolic risk profile than lesser consumption or consumption of refined grains.

Testosterone Therapy Could Improve Cardiovascular Health in Men with Hypogonadism

July 13, 2021

A study from the Annual Congress of the European Association of Urology suggests undergoing testosterone therapy could improve cardiovascular health and reduce risk of adverse events in men with hypogonadism.

DISCOVER Details Gradual Uptake, Need for Improvement in Prescribing of SGLT2 Inhibitors, GLP-1 RAs

July 02, 2021

Insights from the DISCOVER registry were presented at the American Diabetes Association's 81st Scientific Sessions. Check out our Q&A with study presenter Suzanne Arnold, MD, of St. Luke's Mid America Heart Institute.

ADA 2021: Sotagliflozin Impact in Patients with Type 2 Diabetes Highlighted in Special Session

June 29, 2021

While still waiting for regulatory approval, the SCORED and SOLOIST trial have demonstrated the impact of sotagliflozin, a dual SGLT1/2 inhibitor, on patients with type 2 diabetes and chronic kidney disease or heart failure.

AMPLITUDE-O: Efpeglenatide Shows Promise for Reducing CV, Kidney Events in Patients with Diabetes

June 28, 2021

Data from the AMPLITUDE-O trial demonstrates the effects of the exendin-4-based GLP-1 RA efpeglenatide on cardiovascular and renal outcomes among patients with type 2 diabetes and cardiovascular disease or kidney disease.

REDUCE-IT BMI: Icosapent Ethyl Provides Consistent Benefit, Regardless of BMI

June 28, 2021

Deepak Bhatt, MD, MPH, discusses the results of REDUCE-IT BMI, which examined effects of icosapent ethyl vs placebo based on baseline BMI, that he presented at ADA 2021.